FDA Approves HEPARIN SODIUM IN SODIUM CHLORIDE — B. Braun Medical Inc.

B. Braun Medical Inc. received FDA approval on July 20, 1992, for Heparin Sodium in Sodium Chloride marked under NDA019953, solidifying a long-standing position in the anticoagulant market. This retroactive regulatory history reinforces B. Braun’s legacy of providing essential intravenous therapies, though the substance’s legacy status implies the approval is primarily symbolic regarding current commercial requirements.